NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
Neuronetics (NASDAQ: STIM) has announced two peer-reviewed publications in the inaugural edition of the Transcranial Magnetic Stimulation journal, highlighting significant findings about TMS therapy for depression. The first publication demonstrates that transcranial magnetic stimulation (TMS) produces universal improvement in depressive symptoms. The second study reveals that the Patient Health Questionnaire-9 (PHQ-9) shows greater sensitivity compared to the Quick Inventory of Depressive Symptomatology: Self-Report (QIDS-SR) in measuring TMS outcomes.
These publications aim to advance mental health treatment through research and provide clinicians with better tools for patient care. According to Keith J. Sullivan, President and CEO, these findings reinforce TMS's effectiveness in treating depression symptoms while offering insights for more precise clinical care.
Neuronetics (NASDAQ: STIM) ha annunciato due pubblicazioni sottoposte a revisione paritaria nella prima edizione della rivista sulla Stimolazione Magnetica Transcranica, evidenziando scoperte significative riguardo alla terapia TMS per la depressione. La prima pubblicazione dimostra che la stimolazione magnetica transcranica (TMS) produce un miglioramento universale nei sintomi depressivi. Il secondo studio rivela che il Questionario sulla Salute del Paziente-9 (PHQ-9) mostra una maggiore sensibilità rispetto al Quick Inventory of Depressive Symptomatology: Self-Report (QIDS-SR) nel misurare i risultati della TMS.
Queste pubblicazioni mirano a far progredire il trattamento della salute mentale attraverso la ricerca e fornire ai clinici strumenti migliori per la cura dei pazienti. Secondo Keith J. Sullivan, Presidente e CEO, queste scoperte rafforzano l'efficacia della TMS nel trattare i sintomi della depressione, offrendo al contempo spunti per una cura clinica più precisa.
Neuronetics (NASDAQ: STIM) ha anunciado dos publicaciones revisadas por pares en la edición inaugural de la revista de Estimulación Magnética Transcraneal, destacando hallazgos significativos sobre la terapia TMS para la depresión. La primera publicación demuestra que la estimulación magnética transcraneal (TMS) produce una mejora universal en los síntomas depresivos. El segundo estudio revela que el Cuestionario de Salud del Paciente-9 (PHQ-9) muestra una mayor sensibilidad en comparación con el Quick Inventory of Depressive Symptomatology: Self-Report (QIDS-SR) en la medición de los resultados de la TMS.
Estas publicaciones tienen como objetivo avanzar en el tratamiento de la salud mental a través de la investigación y proporcionar a los clínicos mejores herramientas para el cuidado del paciente. Según Keith J. Sullivan, Presidente y CEO, estos hallazgos refuerzan la efectividad de la TMS en el tratamiento de los síntomas de depresión al tiempo que ofrecen ideas para una atención clínica más precisa.
Neuronetics (NASDAQ: STIM)는 최초의 경두개 자기 자극 저널에 게재된 두 개의 동료 평가 출판물을 발표하였으며, 우울증에 대한 TMS 치료에 대한 중요한 발견을 강조하였습니다. 첫 번째 출판물은 경두개 자기 자극 (TMS)이 우울 증상에서 전방위적인 개선을 가져온다는 것을 보여줍니다. 두 번째 연구에서는 환자 건강 질문지-9 (PHQ-9)가 TMS 결과를 측정하는 데 있어 Quick Inventory of Depressive Symptomatology: Self-Report (QIDS-SR)보다 더 높은 민감성을 나타낸다는 것을 밝혀냈습니다.
이 출판물들은 연구를 통해 정신 건강 치료를 발전시키고 임상의들에게 환자 돌봄을 위한 더 나은 도구를 제공하는 것을 목표로 하고 있습니다. Keith J. Sullivan, 사장 겸 CEO에 따르면, 이러한 발견은 우울증 증상 치료에서 TMS의 효과를 강화하고 보다 정밀한 임상 치료를 위한 통찰을 제공합니다.
Neuronetics (NASDAQ: STIM) a annoncé deux publications évaluées par les pairs dans le premier numéro de la revue sur la Stimulation Magnétique Transcrânienne, mettant en avant des résultats significatifs concernant la thérapie TMS pour la dépression. La première publication démontre que la stimulation magnétique transcrânienne (TMS) entraîne une amélioration universelle des symptômes dépressifs. La deuxième étude révèle que le Questionnaire de Santé du Patient-9 (PHQ-9) présente une sensibilité supérieure par rapport à l'Inventaire Rapide des Symptômes Dépressifs : Auto-évaluation (QIDS-SR) dans la mesure des résultats de la TMS.
Ces publications visent à faire avancer le traitement de la santé mentale par la recherche et à fournir aux cliniciens de meilleurs outils pour la prise en charge des patients. Selon Keith J. Sullivan, Président et CEO, ces résultats renforcent l'efficacité de la TMS dans le traitement des symptômes dépressifs tout en offrant des perspectives pour des soins cliniques plus précis.
Neuronetics (NASDAQ: STIM) hat zwei begutachtete Veröffentlichungen in der ersten Ausgabe der Zeitschrift für Transkranielle Magnetstimulation angekündigt, die bedeutende Erkenntnisse über die TMS-Therapie bei Depressionen hervorheben. Die erste Veröffentlichung zeigt, dass transkranielle Magnetstimulation (TMS) eine universelle Verbesserung der depressiven Symptome bewirkt. Die zweite Studie offenbart, dass der Patient Health Questionnaire-9 (PHQ-9) im Vergleich zum Quick Inventory of Depressive Symptomatology: Self-Report (QIDS-SR) eine größere Sensitivität bei der Messung von TMS-Ergebnissen zeigt.
Diese Veröffentlichungen zielen darauf ab, die Behandlung der psychischen Gesundheit durch Forschung zu verbessern und den Klinikern bessere Werkzeuge für die Patientenversorgung zu bieten. Laut Keith J. Sullivan, Präsident und CEO, verstärken diese Ergebnisse die Wirksamkeit von TMS bei der Behandlung von Depressionssymptomen und bieten Einblicke für eine präzisere klinische Versorgung.
- Publication of two peer-reviewed studies validating TMS therapy effectiveness
- Scientific evidence showing universal improvement in depressive symptoms with TMS
- Identification of superior assessment tool (PHQ-9) for measuring treatment outcomes
- None.
Insights
The publication of two landmark studies in the inaugural Transcranial Magnetic Stimulation journal represents a significant strategic advancement for Neuronetics and the broader TMS therapy market. The research delivers three key commercial advantages:
1. Clinical Validation & Market Differentiation: The demonstration of universal symptom improvement provides compelling evidence for NeuroStar's efficacy, strengthening its position against competitors and potentially accelerating market adoption. This high-quality data in a peer-reviewed setting enhances credibility with both clinicians and payers.
2. Operational Optimization: The validation of PHQ-9 as a superior assessment tool has practical implications for treatment centers. More sensitive outcome measurements can lead to:
- Better patient monitoring and treatment optimization
- Improved documentation for insurance reimbursement
- More efficient clinical workflows
3. Strategic Timing & Positioning: Publication in the inaugural edition of a dedicated TMS journal establishes Neuronetics as a scientific leader in this emerging field. This timing is particularly advantageous as the mental health treatment market expands and providers seek evidence-based solutions.
The market implications extend beyond immediate clinical practice. With depression affecting approximately 21 million adults in the U.S. alone, more sensitive assessment tools and validated treatment outcomes could accelerate insurance coverage expansion and provider adoption. This research positions NeuroStar advantageously in the rapidly growing neuromodulation market, estimated to reach
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools
MALVERN, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two peer-reviewed publications in the inaugural edition of the Transcranial Magnetic Stimulation journal. The first provides compelling evidence that transcranial magnetic stimulation (TMS) induces universal improvement in depressive symptoms. The second paper demonstrates the superior sensitivity of one widely used depression assessment (the Patient Health Questionnaire-9, or PHQ-9) over another (the Quick Inventory of Depressive Symptomatology: Self-Report, or QIDS-SR) for measuring TMS outcomes.
“NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and CEO of Neuronetics. “These findings not only reinforce TMS’s powerful ability to improve many symptoms people with depression face, but also provide clinicians with insights on common tools so they can deliver more precise and effective care. These publications further cement NeuroStar’s position as the leader in advancing TMS therapy and shaping the future of depression treatment.”
The following publications highlight key findings about the impact and assessment of TMS therapy:
The Profile of Symptom Change with Transcranial Magnetic Stimulation for Major Depressive Disorder
- About the publication: This analysis explores how TMS influences individual depressive symptoms in a cohort of 578 patients diagnosed with major depressive disorder (MDD). Researchers utilized two validated assessment tools—the PHQ-9 and the QIDS-SR—to evaluate the severity of depressive symptoms, including mood, energy, appetite, self-view, and sleep disturbances, before and after at least 36 TMS treatments. The study also examined three distinct TMS protocols to compare their effectiveness.
- Results: The data revealed that TMS has a broad antidepressant effect, improving all depressive symptoms with similar magnitude rather than targeting specific symptoms. This challenges a theory in the scientific community that TMS coil positioning should be modified according to the specific depressive symptoms being targeted. Rather, standard clinical TMS appears to function as a comprehensive treatment option for a wide range of depressive symptom profiles. Furthermore, the study found that all three TMS protocols studied were equally effective, giving clinicians greater flexibility in treatment delivery while maintaining consistent results.
Comparison of the PHQ-9 and the QIDS-SR in Assessing the Antidepressant Effects of Transcranial Magnetic Stimulation: Sensitivity to Change
- About the publication: This evaluation compared the sensitivity and reliability of two commonly used depression assessment tools—the PHQ-9 and the QIDS-SR—in capturing symptom improvements following TMS treatment. Data from 578 patients were retrospectively analyzed to evaluate how well each tool reflected changes in depressive symptom severity.
- Results: The PHQ-9 demonstrated superior sensitivity to symptom improvement and identified higher remission rates than the QIDS-SR. Additionally, the PHQ-9 showed stronger reliability in measuring depression severity as a single factor. In contrast, the QIDS-SR was less sensitive, often underreporting symptoms prior to treatment and improvements following treatment; it also categorized more patients as “non-responders.” These findings suggest that the PHQ-9 is a more sensitive measure of TMS-induced changes in depressive symptoms.
“The two publications provide clinicians with valuable insights regarding how best to measure the benefits of TMS and its impact on patients’ symptoms. The first paper demonstrates the effects of TMS are generalized, meaning all depressive symptoms improve relatively equally; this implies that TMS has a widespread impact across different parts of the brain responsible for depressive symptoms,” said Dr. Harold A. Sackeim, Professor, Department of Psychiatry, Medical University of South Carolina. “The second paper shows the PHQ-9 is a superior scale to measure patient progress than the QIDS-SR, which will impact how the clinical field uses these common measurement tools.”
By providing robust evidence of TMS’s effectiveness and actionable insights for clinicians, Neuronetics continues to lead the charge in transforming depression treatment. For more information about NeuroStar Advanced Therapy, please visit www.neurostar.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 6.9 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) CIII Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.68 million treatments to over 51,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
FAQ
What are the key findings of Neuronetics' (STIM) latest TMS therapy research publications?
How does the PHQ-9 compare to QIDS-SR in measuring TMS therapy outcomes for STIM?
What impact do these publications have on NeuroStar's (STIM) market position?
How do the January 2025 research findings support STIM's TMS therapy effectiveness?
